Kyntra Bio
KYNB
164 hedge funds and large institutions have $657M invested in Kyntra Bio in 2021 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 54 increasing their positions, 49 reducing their positions, and 39 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 49
0.17% less ownership
Funds ownership: 2.94% → 2.77% (-0.17%)
6% less call options, than puts
Call options by funds: $6.79M | Put options by funds: $7.23M
6% less funds holding
Funds holding: 175 → 164 (-11)
21% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 39
64% less capital invested
Capital invested by funds: $1.8B → $657M (-$1.15B)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$43.8M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$16.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.7M |
| 4 |
Two Sigma Investments
New York
|
+$15.4M |
| 5 |
Millennium Management
New York
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$105M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.4M |
| 3 |
Janus Henderson Group
London,
|
-$32.6M |
| 4 |
Bank of New York Mellon
New York
|
-$25.2M |
| 5 |
JP Morgan Chase
New York
|
-$13.8M |
KYNB Hedge Fund Activity: Q3 2021 in Review
164 of the 5,727 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2021, worth a combined $657M — down 64% from $1.8B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of KYNB and 31 opened new positions — a net loss of 8 holders — while 49 trimmed existing stakes and 54 added.
The largest buyer was State Street, adding an estimated $43.8M. The largest seller was HHLR Advisors, exiting entirely with an estimated $105M sold.
- 164 institutional investors held Kyntra Bio (KYNB) as of Q3 2021, down from 175 in Q2 2021.
- Funds reported $657M of Kyntra Bio stock for Q3 2021, down 64% quarter-over-quarter.
- 31 funds opened new Kyntra Bio positions in Q3 2021 and 39 closed out, a net change of -8 holders.
- The largest Kyntra Bio buyer in Q3 2021 was State Street, an estimated $43.8M added.
- The largest Kyntra Bio seller in Q3 2021 was HHLR Advisors, an estimated $105M sold.
Based on aggregated 13F filings for Q3 2021.